Search

Your search keyword '"Guillerm, Gaelle"' showing total 153 results
Start Over Author "Guillerm, Gaelle" Publication Type Academic Journals
153 results on '"Guillerm, Gaelle"'

1. Outcome of patients with newly diagnosed AML admitted to the ICU, including preemptive admission – a multi-center study

Author

Desprez, Christophe, Kouatchet, Achille, Marchand, Tony, Mear, Jean Baptiste, Tadié, Jean Marc, Peterlin, Pierre, Chevalier, Patrice, Canet, Emmanuel, Couturier, Marie-Anne, Guillerm, Gaelle, Bodenes, Laetitia, Gyan, Emmanuel, Villate, Alban, Ehrmann, Stephan, Lebreton, Anne, Lester, Marie-Antoinette, Fronteau, Clémentine, Larhantec, Gaelle, André, Virginie, Riou, Jérémie, Hunault-Berger, Mathilde, Schmidt-Tanguy, Aline, and Orvain, Corentin

Published
2023
Full Text
View/download PDF

3. Nilotinib efficacy and safety as salvage treatment following imatinib intolerance and/or inefficacy in steroid refractory chronic graft-versus-host-disease (SR-cGVHD): a prospective, multicenter, phase II study on behalf of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)

Author

Srour, Micha, Alsuliman, Tamim, Labreuche, Julien, Bulabois, Claude-Eric, Chevallier, Patrice, Daguindau, Etienne, Forcade, Edouard, François, Sylvie, Guillerm, Gaelle, Coiteux, Valerie, Turlure, Pascal, Beguin, Yves, Yakoub-Agha, Ibrahim, and Magro, Leonardo

Published
2023
Full Text
View/download PDF

4. Improving Diagnosis of Pulmonary Mucormycosis: Leads From a Contemporary National Study of 114 Cases

Author

Freymond, Nathalie, Sénéchal, Agathe, Belhabri, Amine, Menotti, Jean, Persat, Florence, Coste, Anne, Conrad, Anne, Porcher, Raphaël, Poirée, Sylvain, Peterlin, Pierre, Defrance, Claire, Letscher-Bru, Valérie, Morio, Florent, Gastinne, Thomas, Bougnoux, Marie-Elisabeth, Suarez, Felipe, Nevez, Gilles, Dupont, Damien, Ader, Florence, Halfon-Domenech, Carine, Ducastelle-Leprêtre, Sophie, Botterel, Françoise, Millon, Laurence, Guillerm, Gaelle, Ansart, Séverine, Boutoille, David, Ledoux, Marie-Pierre, Herbrecht, Jean-Etienne, Robin, Christine, Melica, Giovanna, Danion, François, Blanchard, Elodie, Paccoud, Olivier, Garcia-Hermoso, Dea, Lortholary, Olivier, Herbrecht, Raoul, and Lanternier, Fanny

Published
2023
Full Text
View/download PDF

5. Gilteritinib activity in refractory or relapsed FLT3-mutated acute myeloid leukemia patients previously treated by intensive chemotherapy and midostaurin: a study from the French AML Intergroup ALFA/FILO

Author

Dumas, Pierre-Yves, Raffoux, Emmanuel, Bérard, Emilie, Bertoli, Sarah, Hospital, Marie-Anne, Heiblig, Maël, Desbrosses, Yohann, Bonmati, Caroline, Pautas, Cécile, Lambert, Juliette, Orvain, Corentin, Banos, Anne, Pasquier, Florence, Peterlin, Pierre, Marchand, Tony, Uzunov, Madalina, Frayfer, Jamilé, Turlure, Pascal, Cluzeau, Thomas, Jourdan, Eric, Himberlin, Chantal, Tavernier, Emmanuelle, Villate, Alban, Haiat, Stephanie, Chretien, Marie-Lorraine, Carre, Martin, Chantepie, Sylvain, Vaida, Ioana, Wemeau, Mathieu, Chebrek, Safia, Guillerm, Gaelle, Guièze, Romain, Debarri, Houria, Gehlkopf, Eve, Laribi, Kamel, Marcais, Ambroise, Santagostino, Alberto, Béné, Marie-Christine, Mineur, Ariane, Pigneux, Arnaud, Dombret, Hervé, and Récher, Christian

Published
2023
Full Text
View/download PDF

8. In-depth time-dependent analysis of the benefit of allo-HSCT for elderly patients with CR1 AML: a FILO study

Author

Devillier, Raynier, Forcade, Edouard, Garnier, Alice, Guenounou, Sarah, Thepot, Sylvian, Guillerm, Gaelle, Ceballos, Patrice, Hicheri, Yosr, Dumas, Pierre-Yves, Peterlin, Pierre, Hunault-Berger, Mathilde, Béné, Marie-Christine, Bouvier, Anne, Chevallier, Patrice, Blaise, Didier, Vey, Norbert, Pigneux, Arnaud, Récher, Christian, and Huynh, Anne

Published
2022
Full Text
View/download PDF

9. Comparison of mycophenolate mofetil and calcineurin inhibitor versus calcineurin inhibitor-based graft-versus-host-disease prophylaxis for matched unrelated donor transplant in acute myeloid leukemia. A study from the ALWP of the EBMT

Author

Paviglianiti, Annalisa, Labopin, Myriam, Blaise, Didier, Socié, Gerard, Bulabois, Claude Eric, Lioure, Bruno, Ceballos, Patrice, Blau, Igor Wolfgang, Guillerm, Gaelle, Maertens, Johan, Chevallier, Patrice, Huynh, Anne, Turlure, Pascal, Deconinck, Eric, Forcade, Edouard, Nagler, Arnon, and Mohty, Mohamad

Published
2021
Full Text
View/download PDF

11. Late relapse after hematopoietic stem cell transplantation for acute leukemia: a retrospective study by SFGM-TC

Author

Kaphan, Eléonore, Bettega, François, Forcade, Edouard, Labussière-Wallet, Hélène, Fegueux, Nathalie, Robin, Marie, Peffault De Latour, Régis, Huynh, Anne, Lapierre, Léopoldine, Berceanu, Ana, Marcais, Ambroise, Debureaux, Pierre-Edouard, Vanlangendonck, Nicolas, Bulabois, Claude-Eric, Magro, Leonardo, Daniel, Adrien, Galtier, Jean, Lioure, Bruno, Chevallier, Patrice, Antier, Chloé, Loschi, Michael, Guillerm, Gaelle, Mear, Jean-Baptiste, Chantepie, Sylvain, Cornillon, Jérome, Rey, Gaelle, Poire, Xavier, Bazarbachi, Ali, Rubio, Marie-Thérèse, Contentin, Nathalie, Orvain, Corentin, Dulery, Rémy, Bay, Jacques Olivier, Croizier, Carolyne, Beguin, Yves, Charbonnier, Aude, Skrzypczak, Caroline, Desmier, Déborah, Villate, Alban, Carré, Martin, and Thiebaut-Bertrand, Anne

Published
2023
Full Text
View/download PDF

12. Allogeneic Stem Cell Transplantation in Therapy-Related Myelodysplasia after Autologous Transplantation for Lymphoma: A Retrospective Study of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy

Author

Jaimes-Albornoz, Daniel, Mannone, Lionel, Nguyen-Quoc, Stéphanie, Chalandon, Yves, Chevallier, Patrice, Mohty, Mohamad, Meunier, Mathieu, Robin, Marie, Ledoux, Marie-Pierre, Guillerm, Gaëlle, Bay, Jacques-Olivier, Poiré, Xavier, Maillard, Natacha, Leclerc, Mathieu, Daguindau, Etienne, Beguin, Yves, Rubio, Marie Thérèse, and Gyan, Emmanuel

Published
2019
Full Text
View/download PDF

13. Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study

Author

Rea, Delphine, Nicolini, Franck E., Tulliez, Michel, Guilhot, François, Guilhot, Joelle, Guerci-Bresler, Agnès, Gardembas, Martine, Coiteux, Valérie, Guillerm, Gaelle, Legros, Laurence, Etienne, Gabriel, Pignon, Jean-Michel, Villemagne, Bruno, Escoffre-Barbe, Martine, Ianotto, Jean-Christophe, Charbonnier, Aude, Johnson-Ansah, Hyacinthe, Noel, Marie-Pierre, Rousselot, Philippe, and Mahon, François-Xavier

Published
2017
Full Text
View/download PDF

14. Early Post-Transplantation Serum Ferritin Level Predicts Survival in Recipients of Haploidentical Stem Cell Transplantation Using Post-Transplantation Cyclophosphamide as Graft-versus-Host Disease Prophylaxis

Author

Jullien, Maxime, Orvain, Corentin, Berceanu, Ana, Couturier, Marie-Anne, Guillaume, Thierry, Peterlin, Pierre, Garnier, Alice, Bourgeois, Amandine Le, Klemencie, Marion, Schmidt, Aline, Hunault, Mathilde, Daguindau, Etienne, Roussel, Xavier, Delepine, Pascal, Guillerm, Gaelle, Giltat, Aurelien, François, Sylvie, Thepot, Sylvain, Gouill, Steven Le, Béné, Marie-C., and Chevallier, Patrice

Published
2021
Full Text
View/download PDF

16. Management of Myelodysplastic Syndrome Relapsing after Allogeneic Hematopoietic Stem Cell Transplantation: A Study by the French Society of Bone Marrow Transplantation and Cell Therapies

Author

Guièze, Romain, Damaj, Gandhi, Pereira, Bruno, Robin, Marie, Chevallier, Patrice, Michallet, Mauricette, Vigouroux, Stéphane, Beguin, Yves, Blaise, Didier, El Cheikh, Jean, Roos-Weil, Damien, Thiebaut, Anne, Rohrlich, Pierre-Simon, Huynh, Anne, Cornillon, Jérôme, Contentin, Nathalie, Suarez, Felipe, Lioure, Bruno, Mohty, Mohamad, Maillard, Natacha, Clement, Laurence, François, Sylvie, Guillerm, Gaëlle, and Yakoub-Agha, Ibrahim

Published
2016
Full Text
View/download PDF

17. Improving Diagnosis of Pulmonary Mucormycosis: Leads From a Contemporary National Study of 114 Cases.

Author

Coste, Anne, Conrad, Anne, Porcher, Raphaël, Poirée, Sylvain, Peterlin, Pierre, Defrance, Claire, Letscher-Bru, Valérie, Morio, Florent, Gastinne, Thomas, Bougnoux, Marie-Elisabeth, Suarez, Felipe, Nevez, Gilles, Dupont, Damien, Ader, Florence, Halfon-Domenech, Carine, Ducastelle-Leprêtre, Sophie, Botterel, Françoise, Millon, Laurence, Guillerm, Gaelle, and Ansart, Séverine

Subjects
MUCORMYCOSIS, HEMATOPOIETIC stem cell transplantation, SYMPTOMS, DIAGNOSIS
Abstract

Pulmonary mucormycosis (PM) is a life-threatening invasive mold infection. Diagnosis of mucormycosis is challenging and often delayed, resulting in higher mortality. Are the disease presentation of PM and contribution of diagnosis tools influenced by the patient's underlying condition? All PM cases from six French teaching hospitals between 2008 and 2019 were retrospectively reviewed. Cases were defined according to updated European Organization for Research and Treatment of Cancer/Mycoses Study Group criteria with the addition of diabetes and trauma as host factors and positive serum or tissue PCR as mycologic evidence. Thoracic CT scans were reviewed centrally. A total of 114 cases of PM were recorded, including 40% with disseminated forms. Main underlying conditions were hematologic malignancy (49%), allogeneic hematopoietic stem cell transplantation (21%), and solid organ transplantation (17%). When disseminated, main dissemination sites were the liver (48%), spleen (48%), brain (44%), and kidneys (37%). Radiologic presentation included consolidation (58%), pleural effusion (52%), reversed halo sign (26%), halo sign (24%), vascular abnormalities (26%), and cavity (23%). Serum quantitative polymerase chain reaction (qPCR) was positive in 42 (79%) of 53 patients and BAL in 46 (50%) of 96 patients. Results of transthoracic lung biopsy were diagnostic in 8 (73%) of 11 patients with noncontributive BAL. Overall 90-day mortality was 59%. Patients with neutropenia more frequently displayed an angioinvasive presentation, including reversed halo sign and disseminated disease (P <.05). Serum qPCR was more contributive in patients with neutropenia (91% vs 62%; P =.02), and BAL was more contributive in patients without neutropenia (69% vs 41%; P =.02). Serum qPCR was more frequently positive in patients with a > 3 cm main lesion (91% vs 62%; P =.02). Overall, positive qPCR was associated with an early diagnosis (P =.03) and treatment onset (P =.01). Neutropenia and radiologic findings influence disease presentation and contribution of diagnostic tools during PM. Serum qPCR is more contributive in patients with neutropenia and BAL examination in patients without neutropenia. Results of lung biopsies are highly contributive in cases of noncontributive BAL. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

18. Antithymocyte Globulin before Allogeneic Stem Cell Transplantation for Progressive Myelodysplastic Syndrome: A Study from the French Society of Bone Marrow Transplantation and Cellular Therapy

Author

Duléry, Rémy, Mohty, Mohamad, Duhamel, Alain, Robin, Marie, Beguin, Yves, Michallet, Mauricette, Vigouroux, Stéphane, Lioure, Bruno, Garnier, Alice, El Cheikh, Jean, Bulabois, Claude-Eric, Huynh, Anne, Bay, Jacques-Olivier, Daguindau, Etienne, Ceballos, Patrice, Clément, Laurence, Dauriac, Charles, Maillard, Natacha, Legrand, Faezeh, Cornillon, Jérôme, Guillerm, Gaëlle, François, Sylvie, Lapusan, Simona, Chevallier, Patrice, Damaj, Gandhi, and Yakoub-Agha, Ibrahim

Published
2014
Full Text
View/download PDF

19. In Adults with Ph-Negative Acute Lymphoblastic Leukemia (ALL), Age-Adapted Chemotherapy Intensity and MRD-Driven Transplant Indication Significantly Reduces Treatment-Related Mortality (TRM) and Improves Overall Survival - Results from the Graall-2014 Trial

Author

Boissel, Nicolas, Huguet, Francoise, Leguay, Thibaut, Mathilde, Hunault-Berger, Graux, Carlos, Chalandon, Yves, Delabesse, Eric, Hicheri, Yosr, Chevallier, Patrice, Balsat, Marie, Pastoret, Cedric, Escoffre-Barbe, Martine, Pasquier, Florence, Marolleau, Jean-Pierre, Thiebaut-Bertrand, Anne, Huynh, Anne, Dhedin, Nathalie, Lemasle, Emilie, Bonmati, Caroline, Maury, Sébastien, Guillerm, Gaëlle, Berceanu, Anna, Schanz, Urs, Cluzeau, Thomas, Turlure, Pascal, Rousselot, Philippe, De Prijck, Bernard J.M., Grardel, Nathalie, Bene, Marie C, Lafage, Marine, Ifrah, Norbert, Lheritier, Veronique, Asnafi, Vahid, Clappier, Emmanuelle, and Dombret, Herve

Published
2022
Full Text
View/download PDF

20. Gilteritinib Activity in Refractory or Relapsed FLT3-Mutated Acute Myeloid Leukemia Patients Previously Treated By Intensive Chemotherapy and Midostaurin: A Study from the French AML Intergroup ALFA/Filo

Author

Dumas, Pierre-Yves, Raffoux, Emmanuel, Berard, Emilie, Bertoli, Sarah, Hospital, Marie Anne, Heiblig, Mael, Desbrosses, Yohan, Bonmati, Caroline, Pautas, Cecile, Lambert, Juliette, Orvain, Corentin, Banos, Anne, Pasquier, Florence, Peterlin, Pierre, Marchand, Tony, Uzunov, Madalina, Frayfer, Jamilé, Turlure, Pascal, Cluzeau, Thomas, Jourdan, Eric, Himberlin, Chantal, Tavernier, Emmanuelle, Villate, Alban, Haiat, Stéphanie, Chretien, Marie-Lorraine, Carre, Martin, Chantepie, Sylvain, Vaida, Iona, Wemeau, Mathieu, Chebrek, Safia, Guillerm, Gaëlle, Guieze, Romain, Debarri, Houria, Gehlkopf, Eve, Laribi, Kamel, Marçais, Ambroise, Santagostino, Alberto, Bene, Marie C, Mineur, Ariane C, Pigneux, Arnaud, Dombret, Herve, and Recher, Christian

Published
2022
Full Text
View/download PDF

21. Salvage haploidentical or cord‐blood allogeneic stem cell transplantation after a prior alternative allograft in hematologic malignancies: A retrospective study from the SFGM‐TC.

Author

Cavalieri, Doriane, Rubio, Marie‐Thérèse, Corriger, Alexandrine, Pereira, Bruno, Cabrespine, Aurélie, Robin, Marie, Labussière‐Wallet, Hélène, Calleja, Anne, Forcade, Edouard, Chevallier, Patrice, Guillerm, Gaelle, Berceanu, Ana, Bulabois, Claude‐Eric, Maillard, Natacha, Nguyen, Stéphanie, Raus, Nicole, Schoemans, Hélène, Bay, Jacques‐Olivier, and Ravinet, Aurélie

Subjects
STEM cell transplantation, HEMATOPOIETIC stem cell transplantation, CORD blood transplantation, HEMATOLOGIC malignancies, HOMOGRAFTS, HEMATOPOIETIC stem cells
Abstract

Background: Haploidentical (haplo‐) donors and cord‐blood (CB) stem cells provide alternative transplant options in patients lacking an HLA‐matched donor. In case of relapse or graft failure after a first alternative allogeneic hematopoietic stem cell transplant (HSCT), a second alternative HSCT (HSCT2) is rarely considered due to a high risk of toxicity. Methods: A retrospective French multicentre study was performed, including patients with hematologic malignancies who underwent two consecutive HSCT from alternative donors. All data were exported from the national ProMISE database between 2000 and 2016. Results: Forty‐three patients (61.4%) received a CB‐HSCT2 and 27 (38.6%) a haplo‐HSCT2. Indications for HSCT were graft failure (51.4%) or disease progression (48.6%). Two‐years probabilities of overall survival, progression‐free survival and toxicity‐related mortality were 18.5%, 17.8% and 55.8%, respectively. In multivariate analysis, complete remission status at HSCT2 and year of HSCT2 ≥ 2012 were significantly associated with a better outcome (with respectively hazard ratio [HR] = 0.42, p =.002 and HR = 0.5, p =.051). Conclusions: Neither the indication of HSCT2 nor the source of stem cell was more advantageous towards overall patient survival. A salvage haploidentical or cord‐blood stem cell transplantation is a high‐risk procedure, that may be considered for patients achieving a complete remission before receiving the second HSCT. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

22. Autoimmune and inflammatory manifestations occur frequently in patients with primary immunodeficiencies

Author

Fischer, Alain, Provot, Johan, Jais, Jean-Philippe, Alcais, Alexandre, Mahlaoui, Nizar, Adoue, Daniel, Aladjidi, Nathalie, Amoura, Zahir, Arlet, Philippe, Armari-Alla, Corinne, Bader-Meunier, Brigitte, Barlogis, Vincent, Bayart, Sophie, Beaurain, Beatrice, Bertrand, Yves, Bienvenu, Boris, Blanche, Stéphane, Bodet, Damien, Bonnotte, Bernard, Borie, Raphaël, Boutard, Patrick, Briandet, Claire, Brion, Jean-Paul, Brito, Carolina, Brouard, Jacques, Catherinot, Emilie, Chandesris, Olivia, Cohen-Beaussant, Sarah, Coignard-Biehler, Hélène, Costes, Laurence, Couderc, Louis-Jean, Couillault, Gérard, Courteille, Virginie, Curlier, Elodie, de Saint Basile, Geneviève, Demeocq, François, de Vergnes, Nathalie, Devoldere, Catherine, Deville, Anne, Donadieu, Jean, Dore, Eric, Dulieu, Fabienne, Durieu, Isabelle, Edan, Christine, Werle, Natacha Entz, Fieschi, Claire, Fouyssac, Fanny, Frange, Pierre, Gajdos, Vincent, Galicier, Lionel, Gandemer, Virginie, Gardembas, Martine, Gaud, Catherine, Grosbois, Bernard, Guillerm, Gaelle, Hachulla, Eric, Hamidou, Mohamed, Héritier, Sébastien, Hermine, Olivier, Hoarau, Cyrille, Hoen, Bruno, Hot, Arnaud, Humbert, Sébastien, Jaccard, Arnaud, Jacquot, Serge, Jaussaud, Rolland, Jeandel, Pierre-Yves, Jeziorski, Eric, Kebaili, Kamila, Korganow, Anne-Sophie, Labrune, Philippe, Lambotte, Olivier, Lanternier, Fanny, Larroche, Claire, Le Quellec, Alain, Le Moigne, Emmanuelle, Le Moing, Vincent, Lebranchu, Yvon, Lecuit, Marc, Lefevre, Guillaume, Lemal, Richard, Le Moine, Philippe, Li Thiao Te, Valérie, Lortholary, Olivier, Lutz, Patrick, Magerus-Chatinet, Aude, Malphettes, Marion, Marie-Cardine, Aude, Silva, Nicolas Martin, Masseau, Agathe, Massot, Christian, Mazingue, Françoise, Merlin, Etienne, Michel, Gérard, Millot, Frédéric, Minckes, Odile, Monlibert, Béatrice, Monpoux, Fabrice, Moshous, Despina, Mouthon, Luc, Munzer, Martine, Neven, Bénédicte, Nove-Josserand, Raphaëlle, Oksenhendler, Eric, Ouachée-Chardin, Marie, Pagnier, Anne, Pasquali, Jean-Louis, Pasquet, Marlène, Pellier, Isabelle, Perel, Yves, Perlat, Antoinette, Picard, Capucine, Piguet, Christophe, Plantaz, Dominique, Quartier, Pierre, Rieux-Laucat, Frédéric, Roblot, Pascal, Roger, Pierre-Marie, Rohrlich, Pierre-Simon, Royer, Bruno, Salle, Valéry, Sarrot-Reynauld, Françoise, Servettaz, Amélie, Stephan, Jean-Louis, Schleinitz, Nicolas, Suarez, Felipe, Swiader, Laure, Taque, Sophie, Thomas, Caroline, Tournilhac, Olivier, Thumerelle, Caroline, Vannier, Jean-Pierre, and Viallard, Jean-François

Published
2017
Full Text
View/download PDF

23. Low Nonrelapse Mortality and Prolonged Long-Term Survival after Reduced-Intensity Allogeneic Stem Cell Transplantation for Relapsed or Refractory Diffuse Large B Cell Lymphoma: Report of the Société Française de Greffe de Moelle et de Thérapie Cellulaire

Author

Sirvent, Anne, Dhedin, Nathalie, Michallet, Mauricette, Mounier, Nicolas, Faucher, Catherine, Yakoub-Agha, Ibrahim, Mohty, Mohamad, Robin, Marie, Tabrizi, Reza, Clement, Laurence, Bilger, Karin, Larosa, Fabrice, Contentin, Nathalie, Huyn, Anne, François, Sylvie, Bulabois, Claude-Eric, Ceballos, Patrice, Bourrhis, Jean-Henri, Buzyn, Agnès, Cornillon, Jérôme, Guillerm, Gaelle, de Revel, Thierry, Bay, Jacques-Olivier, Guilhot, François, and Milpied, Noël

Published
2010
Full Text
View/download PDF

24. Outcomes after allogeneic hematopoietic stem cell transplantation for adults with primary mediastinal B cell lymphoma: a SFGM-TC and LYSA study.

Author

Le Calvez, Baptiste, Tessoullin, Benoit, Renaud, Loïc, Botella-Garcia, Carmen, Srour, Micha, Le Gouill, Steven, Guillerm, Gaelle, Gressin, Rémy, Nguyen Quoc, Stéphanie, Furst, Sabine, Chauchet, Adrien, Sibon, David, Lewalle, Philippe, Poiré, Xavier, Maillard, Natacha, Villate, Alban, Loschi, Michael, Paillassa, Jérôme, Beguin, Yves, and Dulery, Rémy

Subjects
RESEARCH, HOMOGRAFTS, CONFIDENCE intervals, GRAFT versus host disease, B cell lymphoma, RETROSPECTIVE studies, DISEASE incidence, MEDIASTINAL tumors, TREATMENT effectiveness, DESCRIPTIVE statistics, HEMATOPOIETIC stem cell transplantation, PROGRESSION-free survival, PROPORTIONAL hazards models, ADULTS
Abstract

Background: Despite therapeutic progress, 10 to 30% of adult patients with primary mediastinal B cell lymphoma (PMBCL) are primary refractory or experience early relapse (R/R). Allogeneic stem cell transplantation (allo-HSCT) thus remains a potentially curative option in this setting. Material and Methods: In this multicenter retrospective study, the outcomes of 33 French and Belgian adult patients allo-transplanted for R/R PMBCL between January 1999 and December 2018, were examined. Results: At allo-HSCT time, patients had received a median of 3 treatment lines, 50% of them were in complete response, 40% in partial response and 10% had a progressive disease. Forty-two percent of the donors were siblings and 39% matched related. The median follow-up for alive patients was 78 months (3.5–157). Considering the whole cohort, 2-year overall survival (OS), progression free survival (PFS) and graft-versus-host disease-free/relapse-free survival (GRFS) were 48% (95%CI: 33–70), 47% (95%CI: 33–68) and 38.5% (95%CI: 25–60) respectively. Cumulative incidence of relapse and non-relapse mortality rates were respectively 34% (95%CI: 18–50) and 18% (95%CI: 7–34). Disease status at transplant was the only factor predicting survivals, patients with progressive disease showing significant lower 2-year PFS (HR: 6.12, 95%CI: 1.32–28.31, p = 0.02) and OS (HR: 7.04, 95%CI: 1.52–32.75, p = 0.013). A plateau was observed for OS and PFS after 4 years with 10 patients alive after this date, suggesting that almost one third of the patients effectively salvaged and undergoing allo-SCT could be cured. Conclusion: This study indicates that allo-HSCT is a valid therapeutic option for R/R PMBCL, providing durable remissions. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

25. Fms-like Tyrosine Kinase 3 Ligand Kinetic Profile Is the Strongest Factor Predicting Refractoriness after Induction and Event-Free Survival in Adults with AML: A Filo Prospective Multicentric Study

Author

Peterlin, Pierre, Gaschet, Joëlle, Bertoli, Sarah, Bernard, Marc, Carre, Martin, Dumas, Pierre-Yves, Hunault, Mathilde, Belhabri, Amine, Banos, Anne, Bonmati, Caroline, Tavernier, Emmanuelle, Guillerm, Gaelle, Bonnet, Sarah, Decroocq, Justine, Saad, Alain, Ojeda-Uribe, Mario, Guieze, Romain, Marchand, Tony, Recher, Christian, Garnier, Alice, Vibet, Marie-Anne, and Chevallier, Patrice

Published
2023
Full Text
View/download PDF

26. Allogeneic Hematopoietic Cell Transplantation in the Elderly Results in Similar Survival with Matched Related or Unrelated and Haploidentical Donors: A Report from the Société Francophone De Greffe De Moelle Et De Thérapie Cellulaire (SFGM-TC)

Author

Ahmad, Imran, Harbi, Samia, Devillier, Raynier, Castilla-Llorente, Cristina, Robin, Marie, Srour, Micha, Bay, Jacques-Olivier, Ceballos, Patrice, Nguyen-Quoc, Stéphanie, Forcade, Édouard, Bulabois, Claude-Éric, Charbonnier, Amandine, Turlure, Pascal, Chantepie, Sylvain, Maury, Sébastien, Loschi, Michael, Labussière-Wallet, Hélène, Marchand, Tony, Schwarz, Marianne, Marçais, Ambroise, Berceanu, Ana, Daguindau, Étienne, Chevallier, Patrice, Huynh, Anne, Mohty, Mohamad, Dulery, Remy, Maertens, Johan, Poiré, Xavier, Maillard, Natacha, Rubio, Marie-Thérèse, Guillerm, Gaëlle, Chalandon, Yves, Ménard, Anne-Lise, and Cornillon, Jérôme

Published
2023
Full Text
View/download PDF

27. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99–06): a randomised trial

Author

Facon, Thierry, Mary, Jean Yves, Hulin, Cyrille, Benboubker, Lotfi, Attal, Michel, Pegourie, Brigitte, Renaud, Marc, Harousseau, Jean Luc, Guillerm, Gaëlle, Chaleteix, Carine, Dib, Mamoun, Voillat, Laurent, Maisonneuve, Hervé, Troncy, Jacques, Dorvaux, Véronique, Monconduit, Mathieu, Martin, Claude, Casassus, Philippe, Jaubert, Jérôme, Jardel, Henry, Doyen, Chantal, Kolb, Brigitte, Anglaret, Bruno, Grosbois, Bernard, Yakoub-Agha, Ibrahim, Mathiot, Claire, and Avet-Loiseau, Hervé

Published
2007
Full Text
View/download PDF

32. Genetic diagnosis of primary immunodeficiencies: A survey of the French national registry

Author

Bellanné-Chantelot, Christine, Bustamante, Jacinta, Chollet-Martin, Sylvie, Drouet, Christian, Fremeaux-Bacchi, Véronique, Kannengiesser, Caroline, Girardin, Virginie, Lambert, Nathalie, Proulle, Valérie, Rosain, Jérémie, Stasia, Marie José, Lyonnet, Dominique Stoppa, Theodorou, Ioannis, Abou-Chahla, Wadih, Adoue, Daniel, Aladjidi, Nathalie, Amoura, Zahir, Armari-Alla, Corinne, Bader-Meunier, Brigitte, Barlogis, Vincent, Bayart, Sophie, Bertrand, Yves, Blanche, Stéphane, Bodet, Damien, Bonnotte, Bernard, Borie, Raphaël, Boutard, Patrick, Briandet, Claire, Brion, Jean-Paul, Brouard, Jacques, Carausu, Liana, Catherinot, Emilie, Cheikh, Nathalie, Cohen-Beaussant, Sarah, Couderc, Louis-Jean, Cougoul, Pierre, Couillault, Gérard, de Saint Basile, Geneviève, Devoldere, Catherine, Deville, Anne, Dore, Eric, Dulieu, Fabienne, Durieu, Isabelle, Werle, Natacha Entz, Fieschi, Claire, Fouyssac, Fanny, Frange, Pierre, Gajdos, Vincent, Galicier, Lionel, Gandemer, Virginie, Gardembas, Martine, Gaud, Catherine, Grosbois, Bernard, Guffroy, Aurélien, Guitton, Corinne, Guillerm, Gaelle, Hachulla, Eric, Hamidou, Mohamed, Haro, Sophie, Hatchuel, Yves, Hermine, Olivier, Hoarau, Cyrille, Hoen, Bruno, Hot, Arnaud, Humbert, Sébastien, Jaccard, Arnaud, Jacquot, Serge, Jaussaud, Rolland, Jeandel, Pierre-Yves, Jeziorski, Eric, Kebaili, Kamila, Korganow, Anne-Sophie, Lambotte, Olivier, Lanternier, Fanny, Larroche, Claire, Le Quellec, Alain, Le Moigne, Emmanuelle, Le Moing, Vincent, Launay, David, Lebranchu, Yvon, Lecuit, Marc, Lefevre, Guillaume, Lemal, Richard, Li-Thiao-Te, Valérie, Lortholary, Olivier, Malphettes, Marion, Marie-Cardine, Aude, Silva, Nicolas Martin, Masseau, Agathe, Massot, Christian, Mazingue, Françoise, Merlin, Etienne, Michel, Gérard, Millot, Frédéric, Monlibert, Béatrice, Monpoux, Fabrice, Moshous, Despina, Mouthon, Luc, Munzer, Martine, Neven, Bénédicte, Nove-Josserand, Raphaëlle, Nouar, Dalila, Oksenhendler, Eric, Ouachée-Chardin, Marie, Pagnier, Anne, Pasquet, Marlène, Pellier, Isabelle, Perel, Yves, Perlat, Antoinette, Piguet, Christophe, Plantaz, Dominique, Quartier, Pierre, Rieux-Laucat, Frédéric, Roblot, Pascal, Rohrlich, Pierre-Simon, Royer, Bruno, Salle, Valéry, Sarrot-Reynauld, Françoise, Servettaz, Amélie, Stephan, Jean-Louis, Schleinitz, Nicolas, Suarez, Felipe, Swiader, Laure, Taque, Sophie, Thomas, Caroline, Tournilhac, Olivier, Thumerelle, Caroline, Vannier, Jean-Pierre, Viallard, Jean-François, Mahlaoui, Nizar, Picard, Capucine, Bach, Perrine, Costes, Laurence, Courteille, Virginie, Ranohavimparany, Anja, Alcaïs, Alexandre, Jais, Jean-Philippe, and Fischer, Alain

Published
2019
Full Text
View/download PDF

36. Impact of allogeneic stem cell transplantation comorbidity indexes after haplotransplant using post‐transplant cyclophosphamide.

Author

Jullien, Maxime, Orvain, Corentin, Berceanu, Ana, Couturier, Marie‐Anne, Guillaume, Thierry, Peterlin, Pierre, Garnier, Alice, Le Bourgeois, Amandine, Klemencie, Marion, Schmidt, Aline, Hunault, Mathilde, Daguindau, Etienne, Roussel, Xavier, Delepine, Pascal, Guillerm, Gaelle, Giltat, Aurelien, François, Sylvie, Thepot, Sylvain, Le Gouill, Steven, and Béné, Marie‐C

Subjects
STEM cell transplantation, HEMATOPOIETIC stem cell transplantation, CYCLOPHOSPHAMIDE, COMORBIDITY, OVERALL survival
Abstract

Background: Three different scoring systems have been developed to assess pre‐transplant comorbidity in allogeneic hematopoietic stem cell transplantation (Allo‐HSCT): the Hematopoietic Cell Transplantation‐Specific Comorbidity Index, the Comorbidity/Age index, and the Augmented Comorbidity/Age index. All were devised to predict overall survival (OS) and disease‐free survival (DFS) survivals and non‐relapse mortality (NRM) in patients receiving HLA‐matched Allo‐HSCT, but their performance has scarcely been studied in the haploidentical Allo‐HSCT setting with post‐transplant cyclophosphamide, a procedure in constant expansion worldwide. Methods: To address this issue, their impact on survivals and NRM was examined in a cohort of 223 patients treated with haploidentical Allo‐HSCT in four different centers. Results: With a median follow‐up of 35.6 months, 3‐year OS, DFS, and NRM were 48.1% ± 4%, 46.3% ± 4%, and 30.0% ± 3%, respectively. No impact was found for any of the three comorbidity scores in univariate analysis. In multivariate analyses, the only three factors associated with lower OS were DRI (p < 0.001), an older age of recipients (≥55 years old, p = 0.02) and of donors (≥40 years old, p = 0.005). Older donor age was also associated with lower DFS and higher NRM. Conclusion: The comorbidity scores do not predict survivals nor NRM in haploidentical Allo‐HSCT with PTCY, suggesting that pre‐transplant comorbidities should not be a contra‐indication to this procedure. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

37. Real Life Study on Allogeneic Hematopoietic Cell Transplantation Practice According to International Guidelines and Its Impact on Survival in Acute Myeloid Leukemia French Population

Author

Abed, Loic, Mounier, Morgane, Robin, Marie, Nguyen Quoc, Stephanie, Raus, Nicole, Berceanu, Anna, Chantepie, Sylvain, Pigneux, Arnaud, Forcade, Edouard, Bay, Jacques-Olivier, Francois, Sylvie, Guillerm, Gaëlle, Mear, Jean-Baptiste, Caillot, Denis, Mohty, Mohamad, Dulery, Remy, Contentin, Nathalie, Jubert, Charlotte, Monnereau, Alain, Orazio, Sebastien, Troussard, Xavier, Cornet, Edouard, Sobh, Mohamad, Maynadie, Marc, and Michallet, Mauricette

Published
2021
Full Text
View/download PDF

39. Allogeneic stem cell transplant in patients with acute myeloid leukemia and karnofsky performance status score less than or equal to 80%: A study from the acute leukemia working party of the European Society for Blood and Marrow Transplantation (EBMT).

Author

Saraceni, Francesco, Labopin, Myriam, Forcade, Edouard, Kröger, Nicolaus, Socié, Gerard, Niittyvuopio, Riitta, Cornelissen, Jan J., Labussière‐Wallet, Hélène, Blaise, Didier, Choi, Goda, Byrne, Jenny L., Guillerm, Gaelle, Marchand, Tony, Esteve, Jordi, Bazarbachi, Ali, Savani, Bipin, Olivieri, Attilio, Nagler, Arnon, and Mohty, Mohamad

Subjects
KARNOFSKY Performance Status, ACUTE myeloid leukemia, STEM cell transplantation, ACUTE leukemia, BONE marrow
Abstract

Limited data are currently available on the outcome of patients with acute myeloid leukemia (AML) undergoing allogeneic stem cell transplantation (allo‐SCT) with a reduced performance status. We herein present the results of a registry study on 2,936 AML patients undergoing allo‐SCT in first remission (CR1) with a Karnofsky Performance Status (KPS) score less than or equal to 80%. Two‐year leukemia‐free survival (LFS), overall survival (OS) and graft‐versus‐host disease (GVHD)‐free, and relapse‐free survival (GRFS) rates were 54%, 59%, and 41%, respectively. In multivariable analysis, patients with a KPS score = 80% had lower non‐relapse mortality (NRM) and superior OS in comparison to patients with a KPS score <80% (p < 0.001). In the subgroup of patients with a KPS score =80%, a reduced‐intensity conditioning (RIC) regimen was associated with an increased risk of relapse (p = 0.002) and lower GRFS (p < 0.001) compared to myeloablative conditioning (MAC). Differently, in patients with a KPS score <80%, a RIC regimen resulted in lower NRM (p < 0.001), whereas relapse incidence did not differ, thus leading to an improved GRFS (p = 0.008) as compared to MAC. A transplant from a matched sibling donor (MSD) was associated with a reduced incidence of grade III‐IV acute GVHD (p < 0.01) and NRM (p < 0.01) in comparison to other donor types. In conclusion, allo‐SCT appears feasible in AML patients with a jeopardized KPS score. Survival is significantly affected by the conditioning intensity, which should be adjusted according to the severity of KPS impairment. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

40. Values of Hematopoietic Cell Transplantation-Specific Comorbidity Index, Comorbidity/Age Index and Augmented Comorbidity/Age Index in Recipients of Haploidentical Stem Cell Transplantation Using Ptcy As Gvhd Prophylaxis: A Retrospective Study of 223 Cases

Author

Jullien, Maxime, François, Sylvie, Berceanu, Ana, Couturier, Marie-Anne, Guillaume, Thierry, Peterlin, Pierre, Garnier, Alice, Le Bourgeois, Amandine, Klemencie, Marion, Schmidt, Aline, Hunault, Mathilde, Daguindau, Etienne, Deconinck, Eric, Guillerm, Gaelle, Giltat, Aurelien, Orvain, Corentin, Thepot, Sylvain, Le Gouill, Steven, Bene, Marie C, and Chevallier, Patrice

Published
2020
Full Text
View/download PDF

41. Allogeneic Stem Cell Transplantation in Patients with Acute Myeloid Leukemia and Poor Karnofsky Performance Status Score. a Study from the Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT)

Author

Saraceni, Francesco, Labopin, Myriam, Forcade, Edouard, Kroger, Nicolaus, Socié, Gerard, Niittyvuopio, Riitta, Cornelissen, Jan, Labussière-Wallet, Hélène, Blaise, Didier, Choi, Goda, Byrne, J., Guillerm, Gaelle, Lamy, Thierry, Esteve, Jordi, Bazarbachi, Ali, Savani, Bipin, Nagler, Arnon, and Mohty, Mohamad

Published
2020
Full Text
View/download PDF

42. Outcome of Ph negative myeloproliferative neoplasms transforming to accelerated or leukemic phase.

Author

Mollard, Lise-Marie, Chauveau, Aurélie, Boyer-Perrard, Françoise, Douet-Guilbert, Nathalie, Houot, Roch, Quintin-Roué, Isabelle, Couturier, Marie-Anne, Dagorne, Anaig, Malou, Mohamed, Le Calloch, Ronan, Luycx, Odile, Thepot, Sylvain, Hunault, Mathilde, Guillerm, Gaelle, Berthou, Christian, Ugo, Valérie, Lippert, Éric, and Ianotto, Jean-Christophe

Subjects
MYELOPROLIFERATIVE neoplasms, LEUKEMIA, AZACITIDINE, CANCER chemotherapy, STEM cell transplantation
Abstract

Myeloproliferative neoplasms (MPN) are chronic disorders that can sometimes evolve into accelerated or leukemic phases. We retrospectively identified 122 patients with such blastic phases. The overall median survival was four months: 10.2 months for patients treated with intensive treatments compared to three months for best supportive care (p = .005). Azacytidine, intensive chemotherapies, or allogeneic stem cell transplantation gave the highest median survivals with 9, 10.2, and 19.4 months, respectively. Accelerated phases (AP) had a longer median survival compared to acute leukemia (4.8 months vs. 3.1 months; p = .02). In this retrospective and observational study, we observe that the longest survivals are seen in patients eligible for intensive treatments. Azacytidine shows interesting results in patients non-fit for intensive chemotherapy. Supportive care should probably be restricted to elderly patients and those with unfavorable karyotype. An early diagnosis of AP could also result in a better survival rate. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

43. Comparison of Mycophenolate Mofetil and a Calcineurin Inhibitor Versus Calcineurin Inhibitor Based Graft-Versus-Host-Disease Prophylaxis for Matched Unrelated Donor Transplant for Acute Myeloid Leukemia. a Study from the ALWP of the EBMT

Author

Paviglianiti, Annalisa, Labopin, Myriam, Blaise, Didier, Socie, Gerard, Bulabois, Claude-Eric, Simand, Celestine, Fegueux, Nathalie, Gerbitz, Armin, Guillerm, Gaëlle, Maertens, Johan, Chevallier, Patrice, Huynh, Anne, Turlure, Pascal, Deconinck, Eric, Forcade, Edouard, Nagler, Arnon, and Mohty, Mohamad

Published
2019
Full Text
View/download PDF

44. Gestion personnalisée du sang (GPS) : expérience du CHRU de Brest

Author

Le Niger, Catherine, Vadam, Christophe, Grayo, Claire Marine, Le Roy, Julie, Huet, Olivier, Bodenes, Laeticia, Aubron, Cécile, Huiban, Brigitte, Nguyen, Vinh, Oilleau, Jean Ferreol, Couturier, Marie Anne, Guillerm, Gaelle, Le Guen, Patrick, Galinat, Hubert, Carré, Jean-Luc, Coutté, Marie-Bénédicte, and Ozier, Yves

Published
2019
Full Text
View/download PDF

47. Comparison of Mobilized Peripheral Blood Stem Cells Versus Unmanipulated Bone Marrow Haploidentical Transplantation Using Post-Transplant Cyclophosphamide: A Retrospective Study of SFGM-TC in 176 Patients

Author

Jacque, Nathalie, Lambert, Jérôme, Yakoub-Agha, Ibrahim, Tabrizi, Reza, Michallet, Mauricette, Deconinck, Eric, Thepot, Sylvain, Meunier, Mathieu, Peffault De Latour, Regis, Suarez, Felipe, Charbonnier, Amandine, Turlure, Pascal, Ceballos, Patrice, Guillerm, Gaelle, Michel, Gerard, Contentin, Nathalie, Marchand, Tony, Mannone, Lionel, Dalle, Jean-Hugues, Malfuson, Jean Valère, Lioure, Bruno, Rubio, Marie Thérèse, and Nguyen, Stephanie

Published
2017
Full Text
View/download PDF

48. Randomized Phase 2 Trial of Lirilumab (anti-KIR monoclonal antibody, mAb) As Maintenance Treatment in Elderly Patients (pts) with Acute Myeloid Leukemia (AML): Results of the Effikir Trial

Author

Vey, Norbert, Dumas, Pierre-Yves, Recher, Christian, Gastaud, Lauris, Lioure, Bruno, Bulabois, Claude-Eric, Pautas, Cecile, Marolleau, Jean-Pierre, Leprêtre, Stéphane, Raffoux, Emmanuel, Thomas, Xavier, Hicheri, Yosr, Bonmati, Caroline, Quesnel, Bruno, Rousselot, Philippe, Castaigne, Sylvie, Jourdan, Eric, Malfuson, Jean Valère, Guillerm, Gaelle, Bouhris, Jean Henri, Ojeda, Mario, Hunault, Mathilde, Ifrah, Norbert, Gardin, Claude, Delannoy, Andre, Beautier, Lucile, Paturel, Carine, Andre, Pascale, Zerbib, Robert, Preudhomme, Claude, Toubert, Antoine, Dulphy, Nicolas, Olive, Daniel, Pigneux, Arnaud, and Dombret, Herve

Published
2017
Full Text
View/download PDF

49. The presence of monoclonal gammopathy in Ph-negative myeloproliferative neoplasms is associated with a detrimental effect on outcomes.

Author

Le Clech, Lenaïg, Sakka, Mehdi, Meskar, Ahmed, Kerspern, Helene, Eveillard, Jean-Richard, Berthou, Christian, Buors, Caroline, Lippert, Eric, Guillerm, Gaelle, Quintin-Roué, Isabelle, Carré, Jean-Luc, and Ianotto, Jean-Christophe

Subjects
MONOCLONAL gammopathies, MYELOPROLIFERATIVE neoplasms, MULTIPLE myeloma, THROMBOCYTOSIS, POLYCYTHEMIA vera, SURVIVAL analysis (Biometry), HEALTH outcome assessment
Abstract

Many case reports have indicated the occurrence of monoclonal gammopathy of uncertain significance (MGUS) or multiple myeloma (MM) in patients with Ph-negative myeloproliferative neoplasms (MPN), but few cohorts of patients have been published. This study concerns 667 patients newly diagnosed with polycythemia vera (PV) or essential thrombocythemia (ET) who were tested for monoclonal (M) protein at diagnosis (13.9% of patients). The overall survival of patients with M protein was dramatically lower than that of patients without M protein (12.7 versus 22.4 years; p = .0132). Univariate analysis identified the presence of M protein as a potential risk factor for the secondary occurrence of myelofibrosis (p = .02), myelodysplastic syndrome (p = .043), and MM/Waldenstrom macroglobulinemia (p < .0001). Our cohort shows that the presence of M proteins in patients with PV or ET leads to a poor prognosis. We believe that testing for M protein could help practicians to identify such patients. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

50. Impact of body-surface area on patients' outcome in younger adults with acute myeloid leukemia.

Author

Cahu, Xavier, Carré, Martin, Recher, Christian, Pigneux, Arnaud, Hunault‐Berger, Mathilde, Vey, Norbert, Chevallier, Patrice, Delaunay, Jacques, Gyan, Emmanuel, Lioure, Bruno, Bonmati, Caroline, Himberlin, Chantal, Hicheri, Yosr, Guillerm, Gaelle, Didier, Bouscary, Larosa, Fabrice, Ojeda‐Uribe, Mario, Bernard, Marc, Bene, Marie C., and Ifrah, Norbert

Subjects
ACUTE myeloid leukemia treatment, CANCER chemotherapy, BODY surface area, HEALTH of adults, HEALTH outcome assessment, SURVIVAL analysis (Biometry)
Abstract

Objectives Anthracyclines and cytarabine are cornerstones for intensive chemotherapy in acute myeloid leukemia (AML). The goals of this study were to comprehensively assess deviations from theoretical doses and the impact of body-surface area (BSA) on patients' characteristics, physicians' strategy, dose adjustment, and clinical outcome. Methods The GOELAMS 2001 phase III trial included 823 AML patients below 60 years of age. In the course of treatment, anthropomorphic parameters and chemotherapy doses were prospectively registered. Results Very high BSA (≥2.15 m2) was the factor most significantly associated with the physician's decision to reduce chemotherapy doses during induction and postremission therapy. Despite similar AML characteristics and therapeutic strategies, the very high BSA group exhibited a significantly worse survival (5-years OS of 27%) compared to the low (BSA≤1.5 m2), intermediate (1.5 m22), or high (2 m22) BSA groups (46%, 47%, 56%, respectively) ( P=.009). In the very high BSA group, dose capping was associated with worse overall survival, although not significantly ( P=.09). Conclusion The presence of a very high BSA is the main reason prompting physicians to reduce chemotherapy doses in adult AML. Furthermore, these patients display a poor outcome and could benefit from full doses calculated on actual BSA. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results